12 Month Price Forecast For DXR
Distance to DXR Price Forecasts
DXR Price Momentum
🤔 Considering Daxor (DXR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 6:03 AM UTC
DXR Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, DXR has a consensus that is bullish. The median price target is $23.38, with forecasts ranging from $22.00 to $24.75. Currently, there are 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With DXR currently trading at $8.09, the median price forecast suggests a 188.9% upside. The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 205.9% upside, while at Maxim Group provides the most conservative target, suggesting a 171.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DXR Analyst Consensus
DXR Price Target Range
Latest DXR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DXR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $24.75 |
| Mar 25, 2021 | Ascendiant Capital | Edward Woo | Buy | Assumes | $21.00 |
| Jul 29, 2019 | Maxim Group | Buy | Initiates | $22.00 | |
| May 16, 2019 | Ascendiant | Buy | Initiates | $0.00 | |
| May 16, 2019 | Ascendiant Capital | Buy | Initiates | $0.00 |
Stocks Similar to Daxor Corp
The following stocks are similar to Daxor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Daxor Corp (DXR) Financial Data
Daxor Corp has a market capitalization of $39.78M with a P/E ratio of 7.1x. The company generates $154,205 in trailing twelve-month revenue with a 1,094.0% profit margin.
Revenue growth is -11.4% quarter-over-quarter, while maintaining an operating margin of -419.2% and return on equity of +5.4%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Daxor Corp (DXR) Company Overview
About Daxor Corp
Medical device company specializing in blood volume measurement.
Daxor Corporation generates revenue by developing and marketing its BVA-100 Blood Volume Analyzer, which offers diagnostic blood testing services. This technology provides clinicians with accurate assessments of a patient's blood volume status, enhancing decision-making in various medical and surgical settings.
Founded in 1971 and headquartered in Oak Ridge, Tennessee, Daxor Corporation was previously known as Idant Corporation before its name change in 1973. The company operates as a subsidiary of the Estate Of Joseph Feldschuh.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
0
CEO
Mr. Michael Richard Feldschuh
Country
United States
IPO Year
1992
Website
www.daxor.comDaxor Corp (DXR) Latest News & Analysis
Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
1 month agoDaxor Corporation (Nasdaq: DXR) is expanding its ezBVA Lab service for blood volume analysis to two new health systems, enhancing outpatient care in nephrology and heart failure.
Daxor's expansion of its ezBVA Lab service indicates growing demand for efficient healthcare solutions, potentially boosting revenue and market position, which could positively impact stock performance.
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
3 months agoDaxor Corporation CEO Michael Feldschuh will join a fireside chat at the 2024 Maxim Healthcare Virtual Summit from October 15-17, highlighting the company's leadership in blood volume measurement.
Daxor's CEO speaking at a major healthcare summit highlights its industry presence and potential growth, influencing investor sentiment and stock performance.
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
3 months agoDaxor Corporation (NASDAQ: DXR) will exhibit at the MedAxiom Cardiovascular Transforum Fall'24 Conference in Aurora, CO, from October 17-19, 2024, focusing on innovation in cardiovascular care.
Daxor Corporation's participation in a key cardiovascular conference highlights its leadership in blood volume measurement, potentially driving innovation and growth in the healthcare sector, impacting investor sentiment.
Daxor Corporation (NASDAQ: DXR) is shifting its regulatory strategy to focus on the 510(k) approval path to expedite the market entry of its new blood volume analyzer.
Daxor's shift to a 510(k) approval path suggests faster market entry for its blood volume analyzer, potentially boosting revenue and enhancing competitive positioning.
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
4 months agoDaxor Corporation (NASDAQ: DXR) will participate in the Heart Failure Society of America's Annual Scientific Meeting from September 27-30, 2024, in Atlanta, focusing on blood volume measurement technology.
Daxor's participation in a major heart failure conference highlights its leadership in a niche market, potentially boosting investor confidence and interest in its growth prospects.
Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
4 months agoDaxor Corporation (Nasdaq: DXR) has launched the ezBVA Lab program to enhance its blood volume analysis services at the 1,000 Bed Comprehensive Medical Center in Oak Ridge, TN.
Daxor Corporation's launch of the ezBVA Lab program enhances its service offerings, potentially increasing revenue and market share in the healthcare sector, impacting investor confidence and stock performance.
Frequently Asked Questions About DXR Stock
What is Daxor Corp's (DXR) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Daxor Corp (DXR) has a median price target of $23.38. The highest price target is $24.75 and the lowest is $22.00.
Is DXR stock a good investment in 2025?
According to current analyst ratings, DXR has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for DXR stock?
Wall Street analysts predict DXR stock could reach $23.38 in the next 12 months. This represents a 188.9% increase from the current price of $8.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Daxor Corp's business model?
Daxor Corporation generates revenue by developing and marketing its BVA-100 Blood Volume Analyzer, which offers diagnostic blood testing services. This technology provides clinicians with accurate assessments of a patient's blood volume status, enhancing decision-making in various medical and surgical settings.
What is the highest forecasted price for DXR Daxor Corp?
The highest price target for DXR is $24.75 from Edward Woo at Ascendiant Capital, which represents a 205.9% increase from the current price of $8.09.
What is the lowest forecasted price for DXR Daxor Corp?
Price targets from Wall Street analysts for DXR are not currently available. The stock is trading at $8.09.
What is the overall DXR consensus from analysts for Daxor Corp?
The overall analyst consensus for DXR is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $23.38.
How accurate are DXR stock price projections?
Stock price projections, including those for Daxor Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
